帕利哌酮缓释片与齐拉西酮片治疗精神分裂症的对照研究

Comparative study of Paliperidone Extended-Release Tablets and Ziprasidone Tablets in treatment of schizophrenia

目的探讨帕利哌酮缓释片治疗精神分裂症的临床疗效及安全性。方法将90例精神分裂症患者随机分为研究组和对照组各45例。研究组给予帕利哌酮缓释片治疗,对照组给予齐拉西酮片治疗,疗程均为8周。以阴性和阳性症状量表(PANSS)、不良反应量表(TESS)分别于治疗前及治疗后2、4、8周评定疗效及安全性。结果两组患者治疗后各时间点PANSS总分及各因子分均明显下降,与治疗前比较,差异有统计学意义(P<0.01);研究组第2、4周末PANSS总分与对照组比较,差异有统计学意义(P<0.05)。研究组锥体外系反应和肝功能异常发生率与对照组比较,差异有统计学意义(P<0.01)。结论帕利哌酮缓释片治疗精神分裂症临床疗效可靠、安全性好。

Objective To investigate the clinical efficacy and safety of Paliperidone Extended-Release Tablets in the treatment of schizophrenia. Methods 90 patients with schizophrenia were randomly divided into the Paliperidone Extended-Release Tablets group （45 cases） and the Ziprasidone Tablets group （45 cases）. Paliperidone Extended-Release Tablets and Ziprasidone Tablets were given to the above two groups for 8 weeks respectively. The Positive and Negative Symptoms Scale （PANSS） and the Treatment Emergent Symptoms Scale（TESS） were adopted to evaluate the effects and the safety before treatment and at 2,4,8 weeks of treatment. Results The total scores and the factor scores of PANSS at various timepoints after treatment in the two groups were significantly decreased, showing statistical difference compared with before treatment（P〈0.01 ）. The total scores of PANSS at the end of 2,4 weeks in the study group had statistical difference compared with the control group（P〈0.05 ）. The extrapyramidal reactions and the abnormity rate of liver function in the study group showed statistical difference compared with the control group （P〈0.01）. Conclusion Paliperidone Extended-Release Tablets has reliable effects with good safety in the treatment of schizophrenia.